Posted by Michael Wonder on 18 Dec 2020
Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis C drugs that are included in the high-cost protection.
In parallel with the review, the regions and pharmaceutical companies have negotiated new side agreements which mean that the costs of hepatitis C drugs are reduced.
This has resulted in the drugs continuing to be included in the high-cost protection for all patients.
